(Q37910901)

25 August 2017

1 reference

title

Difficult-to-treat gouty arthritis: a disease warranting better management (English)

1 reference

25 August 2017

Naomi Schlesinger

1

1 reference

ORCID Public Data File 2021

publication date

1 July 2011

1 reference

25 August 2017

1 reference

25 August 2017

volume

71

1 reference

25 August 2017

issue

11

1 reference

25 August 2017

page(s)

1413-1439

1 reference

Mechanisms of bone erosion in gout: a quantitative analysis using plain radiography and computed tomography.

25 August 2017

cites work

1 reference

https://api.crossref.org/works/10.2165%2F11592290-000000000-00000

The pathogenesis of bone erosions in gouty arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592290-000000000-00000

Gout: on the brink of novel therapeutic options for an ancient disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592290-000000000-00000

Prevalence of comorbid conditions and prescription medication use among patients with gout and hyperuricemia in a managed care setting

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592290-000000000-00000

Adherence with urate-lowering therapies for the treatment of gout

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592290-000000000-00000

Impact of noncompliance with urate-lowering drug on serum urate and gout-related healthcare costs: administrative claims analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592290-000000000-00000

Perceptions of disease and health-related quality of life among patients with gout

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592290-000000000-00000

Gout epidemiology: results from the UK General Practice Research Database, 1990-1999.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592290-000000000-00000

Prescription and comorbidity screening following consultation for acute gout in primary care

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592290-000000000-00000

Gout in the UK and Germany: prevalence, comorbidities and management in general practice 2000-2005

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592290-000000000-00000

Quality of life and disability in patients with treatment-failure gout.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592290-000000000-00000

Thiazide diuretics and the initiation of anti-gout therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592290-000000000-00000

Diuretic induced gout: a multifactorial condition

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592290-000000000-00000

The prevalence of metabolic syndrome in patients with gout: a multicenter study

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592290-000000000-00000

Elevated uric acid increases the risk for kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592290-000000000-00000

Gout is associated with more comorbidities, poorer health-related quality of life and higher healthcare utilisation in US veterans.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592290-000000000-00000

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592290-000000000-00000

The disutility of chronic gout

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592290-000000000-00000

The minimally important difference and patient acceptable symptom state for the Raynaud's condition score in patients with Raynaud's phenomenon in a large randomised controlled clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592290-000000000-00000

Use of "spydergrams" to present and interpret SF-36 health-related quality of life data across rheumatic diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592290-000000000-00000

Canakinumab relieves symptoms of acute flares and improves health-related quality of life in patients with difficult-to-treat Gouty Arthritis by suppressing inflammation: results of a randomized, dose-ranging study

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592290-000000000-00000

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592290-000000000-00000

Physical functioning and mental well-being in association with health outcome in patients enrolled in the Multicenter Automatic Defibrillator Implantation Trial II.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592290-000000000-00000

Validation of the Health Assessment Questionnaire disability index in patients with gout

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592290-000000000-00000

The impact of gout on work absence and productivity.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592290-000000000-00000

Treatment-failure gout: a moving target

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592290-000000000-00000

The economic burden of gout on an employed population.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592290-000000000-00000

Gout in the elderly--a population health study

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592290-000000000-00000

Anti-U3 RNP autoantibodies in systemic sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592290-000000000-00000

Frequency, risk, and cost of gout-related episodes among the elderly: does serum uric acid level matter?

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592290-000000000-00000

The effect of serum urate on gout flares and their associated costs: an administrative claims analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592290-000000000-00000

EULAR evidence based recommendations for gout. Part II: Management. Report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT)

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592290-000000000-00000

A retrospective study of the relationship between serum urate level and recurrent attacks of gouty arthritis: evidence for reduction of recurrent gouty arthritis with antihyperuricemic therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592290-000000000-00000

Management of acute and chronic gouty arthritis: present state-of-the-art

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592290-000000000-00000

Efficacy and safety profile of treatment with etoricoxib 120 mg once daily compared with indomethacin 50 mg three times daily in acute gout: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592290-000000000-00000

Randomised double blind trial of etoricoxib and indometacin in treatment of acute gouty arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592290-000000000-00000

Therapeutic advances in gout.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592290-000000000-00000

Celecoxib versus diclofenac and omeprazole in reducing the risk of recurrent ulcer bleeding in patients with arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592290-000000000-00000

Management of gout in older adults: barriers to optimal control

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592290-000000000-00000

Gout-associated uric acid crystals activate the NALP3 inflammasome

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592290-000000000-00000

High versus low dosing of oral colchicine for early acute gout flare: Twenty-four-hour outcome of the first multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-comparison colchicine study

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592290-000000000-00000

Use of oral prednisolone or naproxen for the treatment of gout arthritis: a double-blind, randomised equivalence trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592290-000000000-00000

Canakinumab for the treatment of acute flares in difficult-to-treat gouty arthritis: Results of a multicenter, phase II, dose-ranging study

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592290-000000000-00000

Treating to target: a strategy to cure gout

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592290-000000000-00000

Lowering serum uric acid levels: what is the optimal target for improving clinical outcomes in gout?

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592290-000000000-00000

Febuxostat compared with allopurinol in patients with hyperuricemia and gout

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592290-000000000-00000

The urate-lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: the CONFIRMS trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592290-000000000-00000

Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase III, randomized, double-blind, parallel-group trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592290-000000000-00000

Concordance of the management of chronic gout in a UK primary-care population with the EULAR gout recommendations

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592290-000000000-00000

Allopurinol is the most common cause of Stevens-Johnson syndrome and toxic epidermal necrolysis in Europe and Israel

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592290-000000000-00000

Pharmacokinetics and pharmacodynamics of febuxostat (TMX-67), a non-purine selective inhibitor of xanthine oxidase/xanthine dehydrogenase (NPSIXO) in patients with gout and/or hyperuricemia

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592290-000000000-00000

EULAR recommendations for the management of large vessel vasculitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592290-000000000-00000

A pilot study of IL-1 inhibition by anakinra in acute gout

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592290-000000000-00000

The interleukin 1 inhibitor rilonacept in treatment of chronic gouty arthritis: results of a placebo-controlled, monosequence crossover, non-randomised, single-blind pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592290-000000000-00000

Canakinumab reduces the risk of acute gouty arthritis flares during initiation of allopurinol treatment: results of a double-blind, randomised study

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592290-000000000-00000

Measuring quality of care for rheumatic diseases using an electronic medical record

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592290-000000000-00000

Primer: inflammasomes and interleukin 1beta in inflammatory disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592290-000000000-00000

Developments in the scientific and clinical understanding of gout

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592290-000000000-00000

Blocking IL-1 in systemic inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592290-000000000-00000

The mechanism of osteoclast differentiation induced by IL-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592290-000000000-00000

Is IL-1 a good therapeutic target in the treatment of arthritis?

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592290-000000000-00000

The human anti-IL-1 beta monoclonal antibody ACZ885 is effective in joint inflammation models in mice and in a proof-of-concept study in patients with rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592290-000000000-00000

Interleukin-1 antagonism in acute gout: is targeting a single cytokine the answer?

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592290-000000000-00000

Serum uric acid-lowering therapies: where are we heading in management of hyperuricemia and the potential role of uricase

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592290-000000000-00000

Hyperuricaemia and gout: state of the art and future perspectives

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592290-000000000-00000

Cytokine-controlled RANKL and osteoprotegerin expression by human and mouse synovial fibroblasts: Fibroblast-mediated pathologic bone resorption

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592290-000000000-00000

Improved health-related quality of life with effective disease-modifying antirheumatic drugs: evidence from randomized controlled trials.

21 January 2018

1 reference

12 December 2020

A survey of current evaluation and treatment of gout

1 reference

12 December 2020

Clinical manifestations of hyperuricemia and gout.

1 reference

12 December 2020

Colchicine for prophylaxis of acute flares when initiating allopurinol for chronic gouty arthritis

1 reference

12 December 2020

1 reference

12 December 2020

Optimal range of serum urate concentrations to minimize risk of gouty attacks during anti-hyperuricemic treatment

1 reference

12 December 2020

Compliance with allopurinol therapy among managed care enrollees with gout: a retrospective analysis of administrative claims.

1 reference

12 December 2020

Is gout associated with reduced quality of life? A case-control study

1 reference

12 December 2020

Uricase formulated with polyethylene glycol (uricase-PEG 20): biochemical rationale and preclinical studies

1 reference

12 December 2020

The association between gout and nephrolithiasis: the National Health and Nutrition Examination Survey III, 1988-1994

1 reference

12 December 2020

Acute gout management during hospitalization: a need for a protocol

1 reference

12 December 2020

Pharmacological management of persistent pain in older persons

1 reference

12 December 2020

Diagnosis of gout: clinical, laboratory, and radiologic findings.

1 reference

12 December 2020

Systemic corticosteroids for acute gout

1 reference

12 December 2020

Gout medication treatment patterns and adherence to standards of care from a managed care perspective

1 reference

12 December 2020

Molecular identification of a renal urate anion exchanger that regulates blood urate levels

1 reference

12 December 2020

Rilonacept (arcalyst), an interleukin-1 trap for the treatment of cryopyrin-associated periodic syndromes.

1 reference

12 December 2020

The prevalence and prophylaxis of gout in England

1 reference

12 December 2020

Treatment of acute gout in hospitalized patients

1 reference

12 December 2020

Clinical presentation and disease associations of gout: a hospital-based study of 100 patients in Singapore.

1 reference

12 December 2020

1 reference

12 December 2020

Treatment of acute attacks of gout with a small dose of intraarticular triamcinolone acetonide

1 reference

12 December 2020

Prophylactic colchicine therapy of intercritical gout. A placebo-controlled study of probenecid-treated patients

1 reference

12 December 2020

Comparison of triamcinolone acetonide with indomethacin in the treatment of acute gouty arthritis

1 reference

12 December 2020

1 reference

12 December 2020

Pegloticase for chronic gout

1 reference

12 December 2020

Prevalence of the metabolic syndrome in patients with gout: the Third National Health and Nutrition Examination Survey

1 reference

12 December 2020

Increasing prevalence of gout and hyperuricemia over 10 years among older adults in a managed care population

1 reference

12 December 2020

Comparison of adrenocorticotropic hormone and triamcinolone acetonide in the treatment of acute gouty arthritis

1 reference

12 December 2020

Uricase protein sequences: conserved during vertebrate evolution but absent in humans

1 reference

12 December 2020

Primary gout in Shantou: a clinical and epidemiological study.

1 reference

12 December 2020

Factors associated with musculoskeletal disability and chronic renal failure in clinically diagnosed primary gout.

1 reference

12 December 2020

10.2165/11592290-000000000-00000

Identifiers

DOI

1 reference

Dimensions Publication ID

25 August 2017

1025418347

0 references

1 reference